SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 OR 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2020
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|850 Maude Avenue, Mountain View, CA||94043|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code: (650) 210-2900
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Name of each exchange
on which registered
|Common Stock, par value $0.001 per share||CCXI||The Nasdaq Stock Market LLC|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1034 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Entry into a Material Definitive Agreement
On October 29, 2020, ChemoCentryx, Inc. (the “Company”) entered into a Manufacturing and Supply Agreement (the “Supply Agreement”) with Vifor Fresenius Medical Care Renal Pharma Ltd. (“Vifor”). Under the Supply Agreement, the Company will supply and sell avacopan drug product to Vifor for commercial use outside of the United States. Vifor will purchase avacopan drug product at a certain percentage mark up to the Company’s cost of goods, in accordance with the Collaboration and License Agreement between the Company and Vifor, dated May 9, 2016, as amended (the “License Agreement”). Vifor’s purchase of avacopan drug product is subject to certain binding forecast periods.
The term of the Supply Agreement expires upon the expiration or termination of the License Agreement. The Supply Agreement may be terminated by either party following an uncured material breach by the other party within forty-five days of written notice of such material breach, or in the event the other party becomes insolvent or subject to bankruptcy proceedings. In addition, Vifor may terminate the Supply Agreement upon occurrence of certain regulatory events or actions, including if Vifor fails to obtain regulatory approval for avacopan in the E.U. or Japan, or if such approval is withdrawn. Commencing five years after the first regulatory approval of avacopan, Vifor may terminate the Supply Agreement for convenience upon six months’ prior written notice.
The Supply Agreement contains representations, warranties and indemnity obligations customary for agreements of this type.
The foregoing description of the terms of the Supply Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Supply Agreement, which will be filed with the Company’s Annual Report on Form 10-K for the year ending on December 31, 2020. The Company intends to redact certain confidential portions of the Supply Agreement because such confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: November 4, 2020|
/s/ Susan M. Kanaya
|Name:||Susan M. Kanaya|
Executive Vice President
Chief Financial and Administrative Officer and Secretary